Biomarkers in systemic lupus erythematosus: I. General overview of biomarkers and their applicability

This publication has 78 references indexed in Scilit:

• The genetics of systemic lupus erythematosus: putting the pieces together
  Genes & Immunity, 2002
• Overview of Biomarkers and Surrogate Endpoints in Drug Development
  Disease Markers, 2002
• Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies
  Annual Review of Pharmacology and Toxicology, 2001
• Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus
  The Journal of Immunology, 2001
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
  Clinical Pharmacology & Therapeutics, 2001
• Single nucleotide polymorphic haplotypes of the interleukin-10 5? flanking region are not associated with renal disease or serology in caucasian patients with systemic lupus erythematosus
  Arthritis & Rheumatism, 1999
• Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus
  Arthritis & Rheumatism, 1998
• Synergistic effect betweenIL-10 andbcl-2 genotypes in determining susceptibility to systemic lupus erythematosus
  Arthritis & Rheumatism, 1998
• The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisal
  British Journal of Clinical Pharmacology, 1997
• Surrogate End Points in Clinical Trials: Are We Being Misled?
  Annals of Internal Medicine, 1996